PDF(Pubmed)
Abstract：
BACKGROUND: Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal. However, few of them have concerned the recurrence risk of prolactinoma following the withdrawal of DAs.
METHODS: Three medical databases, PubMed, EMBASE and Cochrane library, were retrieved up to February, 14, 2021 to identify studies related to recurrence of prolactinoma and withdrawal of DAs. Statistical analyses including meta-analysis, sensitivity analysis, meta-regression, funnel plot and Egger test were performed through software R.
RESULTS: A total of 3225 studies were retrieved from the three data bases, and 13 studies consisted of 616 patients and 19 arms were finally included in this systematic analysis. There was no significant heterogeneity among the included studies, and fixed effect model was thus used. The pooled recurrence proportion of prolactinoma after withdrawal of DA was 2% with a 95% confidence interval (CI) of 1-3%.
CONCLUSIONS: Our study showed a very low recurrent rate of prolactinomas after DAs withdrawal. Much more prospective studies with larger cases and longer follow-up period are encouraged to confirm our finding.
BACKGROUND: Registration number CRD42021245888 (PROSPERO).
METHODS: Three medical databases, PubMed, EMBASE and Cochrane library, were retrieved up to February, 14, 2021 to identify studies related to recurrence of prolactinoma and withdrawal of DAs. Statistical analyses including meta-analysis, sensitivity analysis, meta-regression, funnel plot and Egger test were performed through software R.
RESULTS: A total of 3225 studies were retrieved from the three data bases, and 13 studies consisted of 616 patients and 19 arms were finally included in this systematic analysis. There was no significant heterogeneity among the included studies, and fixed effect model was thus used. The pooled recurrence proportion of prolactinoma after withdrawal of DA was 2% with a 95% confidence interval (CI) of 1-3%.
CONCLUSIONS: Our study showed a very low recurrent rate of prolactinomas after DAs withdrawal. Much more prospective studies with larger cases and longer follow-up period are encouraged to confirm our finding.
BACKGROUND: Registration number CRD42021245888 (PROSPERO).
摘要：
背景：泌乳素瘤是高泌乳素血症的主要原因，多巴胺激动剂（DA）通常是它们的一线治疗。一些研究回顾了DAs停药后高催乳素血症的复发率。然而,他们中很少有人担心停药后催乳素瘤的复发风险。
方法：三个医学数据库，PubMed,EMBASE和Cochrane图书馆，直到2月才被取回，2021年14月14日，确定与泌乳素瘤复发和DAs停药相关的研究。统计分析，包括荟萃分析，敏感性分析，元回归，通过软件R进行漏斗图和Egger测试。
结果：从三个数据库中检索到总共3225项研究，13项研究由616例患者和19组患者组成,最终纳入本系统分析.纳入的研究之间没有显著的异质性，因此使用了固定效应模型。停用DA后泌乳素腺瘤的合并复发比例为2％，95％置信区间（CI）为1-3％。
结论：我们的研究表明，在DAs停药后，泌乳素瘤的复发率非常低。鼓励更多的前瞻性研究，更大的病例和更长的随访期，以证实我们的发现。
背景：注册号CRD42021248888(PROSPERO)。
方法：三个医学数据库，PubMed,EMBASE和Cochrane图书馆，直到2月才被取回，2021年14月14日，确定与泌乳素瘤复发和DAs停药相关的研究。统计分析，包括荟萃分析，敏感性分析，元回归，通过软件R进行漏斗图和Egger测试。
结果：从三个数据库中检索到总共3225项研究，13项研究由616例患者和19组患者组成,最终纳入本系统分析.纳入的研究之间没有显著的异质性，因此使用了固定效应模型。停用DA后泌乳素腺瘤的合并复发比例为2％，95％置信区间（CI）为1-3％。
结论：我们的研究表明，在DAs停药后，泌乳素瘤的复发率非常低。鼓励更多的前瞻性研究，更大的病例和更长的随访期，以证实我们的发现。
背景：注册号CRD42021248888(PROSPERO)。
